Thrombopoietin receptor agonists in chronic primary immune thrombocytopenia: Efficacy of eltrombopag and its role as an alternative to splenectomy

Authors

  • Anna Clara Peres Luz Facultad de Ciencias Médicas, Universidad Privada del Este, filial Ciudad del Este, Paraguay Autor/a
  • Meury Nakano Araújo Marques Facultad de Ciencias Médicas, Universidad Privada del Este, filial Ciudad del Este, Paraguay Autor/a
  • Francine Aquino de Carvalho Almeida Facultad de Ciencias Médicas, Universidad Privada del Este, filial Ciudad del Este, Paraguay Autor/a
  • Eliaquim Frison Hartmann Facultad de Ciencias Médicas, Universidad Privada del Este, filial Ciudad del Este, Paraguay Autor/a
  • Leonardo de Castro Souza Filho Facultad de Ciencias Médicas, Universidad Privada del Este, filial Ciudad del Este, Paraguay Autor/a
  • Breno Alexandre Rocha Oliveira Facultad de Ciencias Médicas, Universidad Privada del Este, filial Ciudad del Este, Paraguay Autor/a
  • Brenda Heloise Padovani Alves Facultad de Ciencias Médicas, Universidad Privada del Este, filial Ciudad del Este, Paraguay Autor/a
  • Paola Britos Facultad de Ciencias Médicas, Universidad Privada del Este, filial Ciudad del Este, Paraguay; ChauxLab Institute, Asunción, Paraguay Autor/a

DOI:

https://doi.org/10.5281/zenodo.21796809

Keywords:

immune thrombocytopenia, eltrombopag, thrombopoietin receptor agonists, splenectomy, sustained platelet response, chronic ITP

Abstract

Background: Primary immune thrombocytopenia (ITP) is an autoimmune disorder that becomes chronic in 60%–70% of adults. First-line treatments such as corticosteroids are associated with high relapse rates and serious adverse effects with prolonged use. Thrombopoietin receptor agonists (TPO-RAs), such as oral eltrombopag, emerged as a therapeutic innovation with a dual thrombopoietic and immunomodulatory mechanism. The aim of this review was to evaluate the efficacy of eltrombopag in achieving a sustained platelet response and its role as an alternative to splenectomy. Methods: An integrative review was conducted following the PRISMA 2020 protocol. A systematic search was performed in four electronic databases, covering evidence from January 2020 to March 2026. Eligibility criteria (PICO framework) focused on adults with chronic/persistent ITP (duration ≥ 3 months, platelets < 30 × 10⁹/L), comparing TPO-RAs with placebo, standard treatment or splenectomy. Outcomes included platelet response (≥ 50 × 10⁹/L), treatment-free sustained remission (TFSR) and splenectomy rate. Results: Fifty-eight studies with more than 18,500 participants were included. Eltrombopag demonstrated statistically significant superiority over placebo for platelet response (RR = 3.42; P < 0.0001), with overall response rates of up to 91% in long-term real-world studies (> 12 months). Induction of TFSR was observed in 25%–53% of patients after gradual discontinuation. Adoption of TPO-RAs was associated with a reduction in the frequency of splenectomies. The safety profile showed hepatic dysfunction (8.2%–22.4%) and thrombotic events (2.2%–3.2%), without a significant increase relative to placebo. Conclusion: Eltrombopag consistently achieves a sustained platelet response superior to placebo and can induce TFSR. Its dual mechanism (thrombopoietic and immunomodulatory) supports its position as a preferred medical alternative to splenectomy in chronic ITP refractory to first-line therapy. Future research priorities include identification of TFSR biomarkers and economic analyses in low-resource health systems.

References

Tărniceriu CC, Hurjui LL, Florea ID, Hurjui I, Grădinaru I, Tănase DM, et al. Immune thrombocytopenic purpura as a hemorrhagic versus thrombotic disease: an updated insight into pathophysiological mechanisms. Medicina (Kaunas). 2022;58(2):211. https://doi.org/10.3390/medicina58020211

Castelli R, Atzori E, Delitala AP, Masala SA, Micheluzzi V, Ponti E, et al. Case report: dangerous liaisons between splenectomy and eltrombopag-induced chronic thromboembolic pulmonary hypertension in patients with immune thrombocytopenia: report of two cases and review of the literature. Front Cardiovasc Med. 2025;12:1508574. https://doi.org/10.3389/fcvm.2025.1508574

González-López TJ, Newland A, Provan D. Current concepts in the diagnosis and management of adult primary immune thrombocytopenia: our personal view. Medicina (Kaunas). 2023;59(4):815. https://doi.org/10.3390/medicina59040815

Hamed EM, Ibrahim ARN, Meabed MH, Khalaf AM, El Demerdash DM, Elgendy MO, et al. Therapeutic outcomes of high dose-dexamethasone versus prednisolone + azathioprine, rituximab, eltrombopag, and romiplostim strategies in persistent, chronic, refractory, and relapsed immune thrombocytopenia patients. Pharmaceuticals (Basel). 2023;16(9):1215. https://doi.org/10.3390/ph16091215

Cuker A, Liebman HA. Corticosteroid overuse in adults with immune thrombocytopenia: cause for concern. Res Pract Thromb Haemost. 2021;5(6):e12592. https://doi.org/10.1002/rth2.12592

Gilreath J, Lo M, Bubalo J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs. 2021;81(11):1285-305. https://doi.org/10.1007/s40265-021-01553-7

Kapur R. Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists. Br J Haematol. 2022;198(5):803-4. https://doi.org/10.1111/bjh.18332

Lozano ML, Segú-Vergés C, Coma M, Álvarez-Román MT, González-Porras JR, Gutiérrez L, et al. Elucidating the mechanism of action of the attributed immunomodulatory role of eltrombopag in primary immune thrombocytopenia: an in silico approach. Int J Mol Sci. 2021;22(13):6907. https://doi.org/10.3390/ijms22136907

Liu Y, Zhang N, Jiang T, Li Y, Xiong Y, Liu Y. Efficacy and safety analysis of thrombopoietin receptor agonists for the treatment of immune thrombocytopenia in adults: analysis of a systematic review and network meta-analysis of randomized controlled trials and results of real-world safety data. Front Med (Lausanne). 2025;12:1531824. https://doi.org/10.3389/fmed.2025.1531824

Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study. Br J Haematol. 2022;197(3):359-66. https://doi.org/10.1111/bjh.18081

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71

Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005;52(5):546-53. https://doi.org/10.1111/j.1365-2648.2005.03621.x

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https://doi.org/10.1136/bmj.i4919

Al-Samkari H, Grace RF, Kuter DJ. The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 2020;11:2040620720912992. https://doi.org/10.1177/2040620720912992

Ahmed HAW, Masoud AT, Han J, Adel Sofy A, Saeed Ahmed A, Abdesattart AT, et al. Eltrombopag effectiveness and tolerability in chronic immune thrombocytopenia: a meta-analysis. Clin Appl Thromb Hemost. 2021;27:10760296211005555. https://doi.org/10.1177/10760296211005555

Lucchini E, Palandri F, Volpetti S, Vianelli N, Auteri G, Rossi E, et al. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. Br J Haematol. 2021;193(2):386-96. https://doi.org/10.1111/bjh.17334

Wong RSM, Yavaşoğlu İ, Yassin MA, Tarkun P, Yoon SS, Wei X, et al. Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE. Blood Adv. 2023;7(17):4773-81. https://doi.org/10.1182/bloodadvances.2022008287

Luo L, Jin S, Song Z, Chong G, Ding H, Zeng S, et al. Bridging the gaps between randomized controlled trials and real-world use of thrombopoietin receptor agonists for adult primary immune thrombocytopenia: a systematic review and meta-analysis. Front Med (Lausanne). 2025;12:1667457. https://doi.org/10.3389/fmed.2025.1667457

Oka S, Ono K, Nohgawa M. The association of lymphocyte phenotypes and outcomes after discontinuing eltrombopag in immune thrombocytopenia. Int J Clin Pract. 2021;75(5):e14057. https://doi.org/10.1111/ijcp.14057

Mageau A, Terriou L, Ebbo M, Souchaud-Debouverie O, Orvain C, Graveleau J, et al. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment. Am J Hematol. 2022;97(1):10-7. https://doi.org/10.1002/ajh.26378

Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia. Am J Hematol. 2023;98(1):122-30. https://doi.org/10.1002/ajh.26497

Cooper N, Guterres S, Pochopień M, Wilson K, James S, Toumi M, et al. The cost-effectiveness of avatrombopag versus eltrombopag and romiplostim in the treatment of patients with immune thrombocytopenia in the UK. J Mark Access Health Policy. 2025;13(2):11. https://doi.org/10.3390/jmahp13020011

Chen M, Fang JP, Zhou CX, Li XY, Lin SF, Xu LH. Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia. Hematology. 2021;26(1):31-6. https://doi.org/10.1080/16078454.2020.1856511

Arnall JR, DiSogra KY, Downing L, Elmes JB, Tran T, Moore DC. Comparative utilization and efficacy of thrombopoietin receptor agonists in relapsed/refractory immune thrombocytopenia. Am J Ther. 2021;28(5):e525-30. https://doi.org/10.1097/mjt.0000000000001335

Osuna-Gómez R, Zamora C, Novelli S, Garcia-Pallarols F, Rodriguez Y, Domingo A, et al. Interplay of leucocyte-platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients. Br J Haematol. 2024;206(4):1200-12. https://doi.org/10.1111/bjh.19779

Zhang P, Miao W. Eltrombopag-induced liver dysfunction during the treatment of immune thrombocytopenia and its risk factors. Ann Palliat Med. 2021;10(6):6419-24. https://doi.org/10.21037/apm-21-1067

Bhattacharjee B, Deka B, Ahmed N. The role of oncology pharmacists in optimizing patient care in chronic immune thrombocytopenia. Eur J Mol Clin Med. 2021;8(3):279-92. https://doi.org/10.31838/ejmcm.08.03.27

Levchenkova OS, Vorobieva VV, Novikov VE, Legonkova TI, Volkova EN. Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia. Research Results in Pharmacology. 2023;9(1):49-59. https://doi.org/10.18413/rrpharmacology.9.10011

Published

2026-07-15

Issue

Section

Review Articles

How to Cite

Thrombopoietin receptor agonists in chronic primary immune thrombocytopenia: Efficacy of eltrombopag and its role as an alternative to splenectomy. (2026). Revista UniNorte De Medicina Y Ciencias De La Salud, 15(2), 44–54. https://doi.org/10.5281/zenodo.21796809

Most read articles by the same author(s)

Similar Articles

1-10 of 269

You may also start an advanced similarity search for this article.